Dr. Edward R. Arrowsmith, MD

Dr. Arrowsmith practices at Erlanger Baroness Hospital in Chattanooga, Tennessee, part of Erlanger Health.

Dr. Arrowsmith's NPI, 1780632687, was assigned on May 4, 2006. Dr. Arrowsmith graduated from Vanderbilt University School of Medicine in 2000. Dr. Arrowsmith holds Tennessee license MD27014.

Dr. Arrowsmith's primary practice is Erlanger Baroness Hospital, at 975 E 3rd St, Chattanooga, TN 37403 in Hamilton County. The practice phone is (423) 778-7000.

Dr. Arrowsmith's primary practice is Erlanger Baroness Hospital in Chattanooga, Tennessee, part of Erlanger Health. Dr. Arrowsmith is also affiliated with CommonSpirit - Memorial Hospital - Chattanooga. The medical group on file is Tennessee Oncology. Dmand AI also links Dr. Arrowsmith to 3 more hospitals, 1 community health center, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Arrowsmith practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Arrowsmith's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Arrowsmith's licenses on file in 2 states: Tennessee and Georgia.

CMS data shows 67,073 Medicare services from Dr. Arrowsmith across 64 procedure codes in 2024, for 1,521 Medicare patients. Medicare paid $1,628,098 for them.

CMS counts 1,521 Medicare patients who saw Dr. Arrowsmith in 2024. The largest group is 75 to 84, with 635 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 14% are also on Medicaid. Their average risk score is 1.95, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Arrowsmith's median patient age at 66, with 57% women.

In 2024, Dr. Arrowsmith wrote 1,860 Medicare Part D claims for 302 patients. 79% of them were for generic drugs. CMS names the drug for 1,601 of them, across 37 drugs with 11 or more claims each, at $5,330,516 in total drug cost. In 2023, CMS named 1,519 claims across 36 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Arrowsmith for performance year 2024, reported as part of a group. Dr. Arrowsmith accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 28 papers to Dr. Arrowsmith, published from 2011 to 2024. 2013 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized and Carcinoma, Renal Cell. Dr. Arrowsmith has published most often in Clin Genitourin Cancer. Dr. Arrowsmith's most frequent co-authors are James A. Reeves, MD, Todd Michael Bauer, MD and John D. Hainsworth, MD.

Dmand AI links Dr. Arrowsmith to 7 clinical trials, 3 of them phase 1/2 studies. 3 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Carcinoma, Acinar Cell and Carcinoma, Adenoid Cystic. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Arrowsmith that name 2 trials.

CMS Open Payments shows 270 general payments to Dr. Arrowsmith from 50 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 58% of the total. Boehringer Ingelheim USA, Inc. paid the most, $8,149. It also lists 4 research payments totaling $13,236 from 2016 to 2018, naming 2 clinical trials.

Dr. Arrowsmith graduated from Vanderbilt University School of Medicine in 2000.